Originally a Harvard University spin out, Platelet Biogenenesis Inc describe themselves as recreating nature's legendary cell. Inspired by platelet biology, the firm's principals are pioneering an entirely new class of cell-based therapeutics.. With exclusive world licences to intellectual property governing the entire differentiation process from stem cell to platelet, the firm is organized around producing donor-independent human platelets from pluripotent stem cells - having created the only platform that can generate human platelets at scale. Addressing stem cell-derived, on-demand platelets -- the first donor-independent source of platelets to address the chronic shortage worldwide - the firm has shown that functional platelets can be generated from human pluripotent stem cell cultures. By removing the volunteer donor, platelets can be made on demand that that are cheaper and safer. Using a microfluidic bioreactor develoed in-house, the firm has shown that functional platelets can be generated from human stem cell cultures at scale. is developing technology to produce the worldâs first donor-independent human platelets from human induced pluripotent stem cells. This technology bridges the gap from megakaryocyte to platelet. Platelets are the âbandaidsâ of the bloodstream, responsible for clot formation and blood vessel repair. Over 2 million Americans receive platelet transfusions annually that dramatically increase survival rates for cancer, transplant, and surgery pati
